Globe Newswire
Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A
- Preliminary blinded CR of 24% and CRc of 37% (n=62), with essentially identical rates among the 30 patients who had failed first-line venetoclax: CR of 23% and CRc of 37% (3X the published salvage remission rates following... (continue reading...)
SASKATOON, Saskatchewan, July 31, 2026 (GLOBE NEWSWIRE) -- Toccata Inc., the Saskatchewan-based technology company behind the remote property monitoring product CabinPulse, today announced Canaro, its next-generation, enterprise-focused monitoring platform with unprecedented connectivity options.
Canaro is a first-in-class remote monitoring platform that supports sensor data transmission from almost anywhere. With built-in Wi-Fi, cellular and satellite connectivity,... (continue reading...)
TUCSON, Ariz., July 31, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, today announced a major milestone in the development of its Emperor Total Artificial Heart (Emperor TAH) program following the first public scientific presentation of the integrated Emperor Total Artificial Heart architecture at the 48th Annual International Conference of the IEEE Engineering in Medicine and... (continue reading...)
VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. ("Greenridge" or the "Company") (CSE: GXP | OTC: GXPLF | FRA: HW3), is pleased to provide an update on the $3.0 million financing (the “Offering”) first reported on July 20, 2026 with a leading Southeast Asian conglomerate that has extensive interests in the global energy sector (the “Corporate Investor”). On July 30, 2026, the Company executed a Sale and Purchase Agreement (the... (continue reading...)
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
The conference call can be... (continue reading...)
More Globe Newswire
View Older Stories-
Steelworkers in Canada welcome American support against Trump tariffs
-
Abercrombie & Fitch Co. to Report Second Quarter 2026 Results on August 26, 2026
-
Mobilicom to Report Financial and Operational Results for the Six Months Ended June 30, 2026, on Thursday, August 13, 2026
-
ATIF Holdings Limited Enters into Definitive Agreement to Acquire GoldCoin Labs Limited
-
Wearable Devices Announces Pricing of $3.3 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
-
From Sponsorship to Commercial Partnership: GSJJ Custom Challenge Coins Case Study with South Carolina Fraternal Order of Police (SCFOP)
-
Space-Eyes and McKinley Acquisition Corp. Announce Definitive Business Combination Agreement to Deliver AI-Driven Counter Drone Technology and Geospatial Intelligence Worldwide
-
Star Group, L.P. to Host Fiscal 2026 Third Quarter Webcast and Conference Call August 6, 2026
-
Swarmer Announces Date for Second Quarter 2026 Results and Business Updates
-
Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended June 30, 2026 and Declaration of Distributions on Common Stock for the Months Ending October
-
Hudbay Announces Correction to its Upcoming Dividend Record and Payment Dates
-
Castellum Schedules Second Quarter 2026 Earnings Release and Conference Call
-
Jushi Holdings Inc. Completes Redomicile from British Columbia to Nevada
-
Abercrombie & Fitch Co. to Report Second Quarter 2026 Results on August 26, 2026
-
Acorn – Provider of Monitoring and Control Solutions for Mission-Critical Assets Hosts Q2 Earnings Call Thursday Aug. 6th at 11am ET
-
J-Star Holding Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
IES Holdings Reports Fiscal 2026 Third Quarter Results and Announces Two-for-One Stock Split
-
Notice on partial early redemption of bonds
-
YXT.com Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
-
Dragonfly Energy Announces Strategic Acquisition of Dakota Lithium Assets, Expanding Into New Markets
-
Multilogin Repositions as a Cloud Phone Platform for Managing Multiple Social Media Accounts, Cuts Entry Price to $7.08/Month
-
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
-
Banco Itaú Chile Announces Second Quarter 2026 Management Commentary
-
DCX Announces Open-Market Share Purchase by Chief Executive Officer
-
IBN.Ai Launches Publicly Traded IBNAi Companion Coin / Token ($IBNAi)
-
IBN.Ai Launches Publicly Traded IBNAi Companion Coin / Token ($IBNAi)
-
Director/PDMR Shareholding
-
Transaction in Own Shares
-
TransAlta Reports Strong Second Quarter Results and Reaffirms Guidance
-
Ocugen to Participate in Upcoming August Investor Conferences
-
GCL Announces Fiscal Year 2026 Financial Results
-
George Weston Limited Reports Adjusted Diluted Net Earnings Per Common Share Growth of 12.9% in the Second Quarter
-
Radiopharm Theranostics Reports Business Update
-
The Orange Giant Announces ZHAI Has Entered Full Production
-
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
-
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
-
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
-
Balchem Corporation Reports Second Quarter 2026 Financial Results
-
LEO Technologies Launches Verus ION, an Agentic AI-Powered Unified Intelligence and Investigative Solution for Corrections and Public Safety
-
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
-
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
-
Green Thumb Expands Pennsylvania Retail Footprint with the Opening of RISE Dispensary Hanover
-
American Tungsten Corp. Begins Trading on OTCQX Best Market
-
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
-
Perella Weinberg Announces Partner Promotions
-
Perella Weinberg Reports Second Quarter 2026 Results
-
Brookfield Renewable Reports Strong Second Quarter Results
-
Bullish to announce second quarter 2026 financial results
